SAN DIEGO, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Martin Auster, M.D. has departed from his role as Chief Financial Officer, effective August 30, 2024. Roy Gonzales, CPA, MBA, the Company's SVP of Finance, has assumed the roles of interim Principal Financial Officer and ...

SAN DIEGO, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) ("Ventyx", "Company"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Company executives will participate in the following upcoming investor conferences: Event: 2024 Wells Fargo Healthcare Conference Location: Boston, MA Date: Wednesday, September 4, 2024 Time: 11:00-11:35 AM ET ...

A Phase 2 obesity and cardiometabolic trial of VTX3232 and a Phase 2a trial of VTX3232 in patients with Parkinson's disease are both expected to initiate in H2 2024 A Phase 2 trial of VTX2735 in recurrent pericarditis is expected to initiate in H2 2024 Mark Forman, MD, PhD will join Ventyx as Chief Medical Officer effective August 12, 2024 Cash, cash equivalents and marketable securities of $279.7 million as of June 30, 2024 are expected to fund planned operations into at least the second half of 2026 SAN D ...

Ventyx Biosciences, Inc. (NASDAQ:VTYX) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Martin Auster - Chief Financial Officer Raju Mohan - Founder and Chief Executive Officer John Nuss - Chief Scientific Officer Conference Call Participants Liam Hiester - Piper Sandler Emily Bodnar - H.C. Wainwright Gospel Enyindah-Asonye - Morgan Stanley Alex Thompson - Stifel Derek Archila - Wells Fargo Sam Slutsky - Life Science Operator Good afternoon, ladies and gentlemen and welcome to th ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number: 001-40928 Ventyx Biosciences, Inc. (Exact Name of Registrant as Specified in its Charter) | Delaware | 83-2996852 | | ...

Exhibit 99.1 Ventyx Biosciences Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Progress Phase 2a trials of CNS-Penetrant NLRP3 Inhibitor VTX3232 to initiate in H2 2024 in patients with early Parkinson's disease and in participants with obesity with certain additional cardiovascular risk factors Cash, cash equivalents and marketable securities of $302.6 million as of March 31, 2024 are expected to fund planned operations into at least the second half of 2026 Ventyx to host confe ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-40928 Ventyx Biosciences, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 83-2996852 (State or other jurisdiction ...

Exhibit 99.1 Ventyx Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Corporate Progress Ventyx to host virtual investor event on March 11 th to provide clinical updates on our NLRP3 portfolio and from the open-label extension of the VTX002 Phase 2 trial in ulcerative colitis Cash, cash equivalents and marketable securities of $252.2 million as of December 31, 2023 are expected to fund operations into at least H2 2025 SAN DIEGO, February 27, 2024 (GLOBE NEWSWIRE) ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number: 001-40928 Ventyx Biosciences, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 83-2996852 (St ...

Ventyx Biosciences, Inc. (NASDAQ:VTYX) Business Update Conference Call Summary Company Overview - **Company**: Ventyx Biosciences, Inc. - **Ticker**: NASDAQ:VTYX - **Date of Call**: November 7, 2023 Key Points Industry and Company Focus - The call focused on the results of the Phase 2 trial of the TYK2 inhibitor VTX958 in plaque psoriasis and provided a business update on ongoing clinical trials and product development [5][6][22]. Clinical Trial Results - The Phase 2 trial of VTX958 in plaque psoriasis achieved its primary and all key secondary endpoints, but did not meet expectations for a best-in-class efficacy profile [5][11]. - A higher-than-anticipated discontinuation rate was observed, with 22% of patients discontinuing at the 225-milligram BID dose and 21% at the 300-milligram BID dose, compared to 16% on placebo [10]. - The trial enrolled 220 participants and was a 16-week randomized, double-blind, placebo-controlled study [8][9]. - The primary endpoint of PASI-75 was achieved by 49% of patients in the 300-milligram BID group, but the overall efficacy was disappointing [11][12]. Decisions on Trials - The company decided to terminate the Phase 2 trial of VTX958 in plaque psoriasis and psoriatic arthritis due to the lack of compelling efficacy data [6][16][17]. - The ongoing Phase 2 trial of VTX958 in Crohn's disease will continue, with an interim efficacy analysis planned for the first quarter of 2024 [17][18]. Financial Position - Ventyx reported having over $300 million in cash, cash equivalents, and marketable securities as of the end of the third quarter, with a cash runway expected to extend into 2025 [24][36]. Future Developments - The company is committed to providing updates on the ongoing Phase 2 trial of VTX958 in Crohn's disease and expects to deliver several important portfolio updates in the first quarter of 2024 [22][25]. - VTX002, an S1P1 modulator for ulcerative colitis, is viewed as a potential best-in-disease oral agent, with updates expected in early 2024 [23][49]. Safety and Adverse Events - Most adverse events in the psoriasis trial were mild or moderate, with no serious adverse events related to the study drug [13]. - A case of colon cancer was reported but deemed unrelated to the drug [43]. Strategic Insights - The company acknowledges a higher unmet need in Crohn's disease and a less competitive landscape for oral agents, which supports the continuation of the trial in this indication [29][35]. - The management expressed confidence in the pharmacokinetic data and the potential for VTX958 to exhibit preferential biodistribution to gastrointestinal tissue [18][32]. Conclusion - While the results from the psoriasis trial were disappointing, Ventyx remains optimistic about its broader portfolio and the potential for upcoming data to inform future development strategies [25][66].